Methods and dosage forms for controlled delivery of alprazolam
First Claim
Patent Images
1. A dosage form comprising a dose of alprazolam, said dosage form effective to provide a dissolution rate where between 25% and 60% of the dose is released 10 hours after exposure to an aqueous environment.
1 Assignment
0 Petitions
Accused Products
Abstract
A dosage form for delivery of alprazolam is described. The sustained release dosage form provides via once-a-day dosing a therapeutically effective average steady-state plasma alprazolam concentration, where the maximum attained plasma concentration is achieved more than about 14 hours after administration. The slow, sustained release reduces side effects such as sedation and abuse potential.
36 Citations
69 Claims
- 1. A dosage form comprising a dose of alprazolam, said dosage form effective to provide a dissolution rate where between 25% and 60% of the dose is released 10 hours after exposure to an aqueous environment.
- 4. A dosage form comprising a dose of alprazolam, said dosage form effective to provide a dissolution rate where between 30% and 80% of the dose is released 12 hours after exposure to an aqueous environment.
-
15. A dosage form, comprising, a dose of alprazolam, said dosage form effective to provide an in vitro release profile where
(i) less than 20% of the dose is released 2 hours after exposure to an aqueous environment; -
(ii) between 25% and 65% of the dose is released 10 hours after exposure to an aqueous environment; and
(iii) greater than 85% of the dose is released 24 hours after exposure to an aqueous environment.
-
- 16. A dosage form for delivery of alprazolam, comprising a dose of alprazolam, the dosage form being configured to release at least about 10% of the dose 16 hours after exposure to an aqueous environment.
- 18. A dosage form for delivery of alprazolam, comprising a dose of alprazolam, the dosage form being configured to release at least about 15% of the dose 14 hours after exposure to an aqueous environment.
- 20. A dosage form for delivery of alprazolam, comprising a dose of alprazolam, the dosage form being configured to release at least about 25% of the dose 12 hours after exposure to an aqueous environment.
- 34. A dosage form for delivering alprazolam comprising a drug formulation including a desired dose of alprazolam, wherein the dosage form is configured to release alprazolam at a rate that ranges between 2% of the total dose of alprazolam per hour to 7% of the total dose of alprazolam per hour over the period of between 2 and 20 hours after exposure to an aqueous environment.
- 37. A dosage form comprising a dose of alprazolam, said dosage form effective to provide cumulative amount of drug released in vivo of between 25% and 60% of the total dose 10 hours after oral delivery.
- 40. A dosage form comprising a dose of alprazolam, said dosage form effective to release between 30% and 80% of the dose 12 hours after oral delivery.
- 51. A dosage form, comprising alprazolam, wherein the dosage form provides a maximum attained alprazolam plasma concentration (Cmax) more than 14 hours after administration.
-
53. A dosage form comprised of a desired dose of alprazolam, said dosage form being effective to provide a dose normalized ratio of maximum attained alprazolam plasma concentration (Cmax) to time to reach maximum attained alprazolam plasma concentration (Tmax) of less than 0.5.
-
55. A dosage form comprising alprazolam, said dosage form providing a dose-normalized area under the curve of less than about 110 ng·
- hr/mL·
mg. - View Dependent Claims (56, 57, 58, 59)
- hr/mL·
-
60. A method for administering alprazolam to a human subject, comprising administering a dosage form effective to provide an in vitro release profile where between 25% and 60% of the dose is released 10 hours after exposure to an aqueous environment.
-
61. A method for administering alprazolam to a human subject, comprising administering a dosage form effective to provide a ratio of maximum attained alprazolam plasma concentration (Cmax) more than 14 hours after administration.
-
62. A method for administering alprazolam to a human subject, comprising administering a dosage form effective to provide a dose-normalized area under the curve of less than about 110 ng·
- hr/mL·
mg.
- hr/mL·
- 63. A method of treating a condition responsive to alprazolam, comprising administering a dosage form effective to provide a dose-normalized area under the curve of less than about 110 ng·
Specification